Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
7
×
life sciences
national blog main
national top stories
new york blog main
7
×
new york top stories
clinical trials
fda
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
drugs
novartis
calcitonin gene-related peptide
cancer
eli lilly
eptinezumab
erenumab
fremanezumab
galcanezumab
marc goodman
What
fda
7
×
new
7
×
drug
approved
medicines
approval
class
fast
gets
medicine
migraine
nod
oks
won
acorda
acquire
activity
agreed
amgen
approvals
arguments
big
billion
bio
biogen
brexanolone
brings
cancer
candidates
cash
cholesterol
clamped
commercialized
companies
company
competitors
compound
cope
covid
deal
Language
unset
Current search:
fda
×
" boston top stories "
×
new
×
" new york blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines